#Sweden #Gothenburg #Zinzino #sales report #Faun Pharma

Zinzino AB Reports Strong Sales Growth in May 2025

Zinzino AB, a notable player in the wellness industry, reported its preliminary sales figures for May 2025, reflecting a remarkable increase in revenue. The company achieved a sales figure of SEK 277.6 million, showing a significant 58% rise compared to SEK 175.5 million from the previous year. This surge is part of a broader trend that has seen the group achieve a total revenue increase of 54% compared to the same period last year, with cumulative revenues reaching SEK 1,261.7 million, a 57% increase year-on-year.

Revenue Breakdown by Region

The impressive sales growth was distributed across various regions, highlighting Zinzino's expanding global footprint:

• - The Nordics: With a steady growth of 14%, the Nordic region generated SEK 29.3 million in May 2025, compared to SEK 25.7 million in the same month last year. Cumulatively, this region has also seen a 9% increase year-to-date, totaling SEK 129.8 million.
• - Central Europe: Notably, Central Europe reported a staggering 49% increase in May sales, amounting to SEK 74.0 million versus SEK 49.5 million, culminating in a 56% rise in cumulative revenue for the year.
• - East Europe: This region showed modest growth, with a 5% increase in May to SEK 36.7 million. Year-to-date, revenue only slightly increased at 1%.
• - South West Europe: Showing robust performance, this region surged by 44% in May, achieving SEK 49.3 million in sales. Cumulatively, it achieved a 66% increase, indicating promising growth potential.
• - The Baltics: Sales grew by 31% to SEK 11.5 million in May, reflecting a solid performance across the Baltic states.
• - North America: Lead by a remarkable 188% increase, North America generated SEK 47.3 million, a sharp rise from SEK 16.4 million. The cumulative revenue surged dramatically by 216%, reaching SEK 212.1 million.
• - Asia-Pacific: The Asia-Pacific region exhibited the most explosive growth, soaring 473% to SEK 27.5 million from just SEK 4.8 million last year, contributing to a staggering cumulative increase of 424%.
• - Africa: This region also grew by 54%, reaching SEK 2.0 million in sales.

Faun Pharma Performance

It is important to note that while Zinzino experienced significant growth, the associated company, Faun Pharma, reported a decline in external sales, dropping 20% to SEK 7.6 million from SEK 9.5 million in May 2024.

Conclusion

The overall performance of Zinzino AB in May 2025 underscores a robust demand for its products in wellness and health, as reflected in its substantial revenue growth across numerous markets. The company's ongoing strategic initiatives, including expansion into North America and the Asia-Pacific regions, appear to be key drivers of this success. Investors and stakeholders remain optimistic about Zinzino's future prospects as the company continues to adapt and evolve in a competitive marketplace, conveniently balancing challenges and opportunities with its diversified portfolio.

For additional information, media representatives can contact CEO Dag Bergheim Pettersen at +47 (0) 932 25 700 or CFO Fredrik Nielsen at +46 (0) 707 900 174.

Zinzino's impressive performance in the first half of 2025 sets the stage for exciting developments ahead as the global appetite for wellness products continues to grow.